As a highly effective oral inhibitor of BCL2, venetoclax was first approved in the r/r treatment setting for CLL patients with del(17p), based on the two phase 2 trials M13-928 [25] and M14-032 [63]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.